Navigation Links
Covance Elects Joseph C. Scodari to Company's Board of Directors
Date:5/8/2008

PRINCETON, N.J., May 8 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Joseph C. Scodari to its Board of Directors.

"We are very pleased to have Joe Scodari join our Board of Directors. He has enjoyed a distinguished 34-year career as a key leader in the pharmaceutical and biotechnology industries, and he has a proven track record of driving growth in large, complex global healthcare businesses," said Joe Herring, Covance chairman and CEO. "In addition, Mr. Scodari's expertise in strategy development and pharmaceutical R&D will help us further strengthen our large client partnerships and enhance our ability to provide productivity solutions that matter."

"Covance's market leadership and broad service offerings position it well to help pharmaceutical companies reduce the time and cost of drug development," Mr. Scodari said. "I look forward to working with Joe and the esteemed group of board members to take advantage of the significant market opportunities in the drug development services industry and continue to drive the company's growth."

Mr. Scodari was recently the worldwide chairman of the Johnson & Johnson (J&J) Pharmaceuticals Group. In this role, he led efforts to improve research and development productivity and build a more robust pipeline. He was also a member of the J&J executive committee and a corporate officer. Before Mr. Scodari was appointed worldwide chairman of J&J's pharmaceutical business in 2005, he was the company group chairman of J&J's global biopharmaceuticals business and was responsible for commercial activities in biotechnology and for specialty businesses in oncology and virology. Under his leadership, Tibotec Therapeutics launched PREZISTA(R) (darunavir), the company's first entry into the HIV market. Previously, Mr. Scodari served as company group chairman for the North America pharmaceuticals business, which included management responsibility for Ortho-McNeil, Janssen Pharmaceutica, and Janssen-Ortho Inc., Canada. Prior to these roles, he served as president and COO, and as a director of Centocor, Inc. and led the organization's transformation from a focus on research and development to a fully integrated biopharmaceutical company. Mr. Scodari has also held leadership positions in Rhone-Poulenc Rorer Pharmaceuticals and Sterling Drug, Inc.

Mr. Scodari recently served as the vice chairman of the board and member of the executive committee of the Biotechnology Industry Organization (BIO). He has also served on the Board of Overseers of the Robert Wood Johnson School of Medicine and on the Board of Trustees of The University of the Sciences in Philadelphia. He was also previously a member of the Board of Directors of Pharmacyclics, Inc., a biopharmaceutical company focused on therapies for cancer. He has a B.A. from Youngstown State University.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the UBS Global Life Sciences Conference
2. Covance Elects Dr. Gary E. Costley to Board of Directors
3. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
4. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
5. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
6. Covance and Care Partner on Rwanda Early Childhood Development Initiative
7. Wendel Barr Appointed Chief Operating Officer of Covance
8. Covance to Present at 26th Annual JPMorgan Healthcare Conference
9. Covance to Present at UBS Global Healthcare Services Conference
10. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
11. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: